ClinicalTrials.gg
CompletedNCT06040918Updated Oct 14, 2025

Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

A Phase 1 interventional study of N-803 in Healthy Subjects, sponsored by ImmunityBio, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by ImmunityBio, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is phase 1 single cohort study evaluating the effects of N-803 administration on mononuclear cells (MNC) collected from healthy donors undergoing a procedure called apheresis.

Read the detailed description

This phase 1, single cohort study will enroll up to 10 healthy subjects. All subjects will be pre-screened for eligibility. If the subject meets eligibility for study participation, informed consent will be obtained. Screening will include a history and physical, review of concomitant medications, assessment of NYHA functional status, assessment of ECOG performance status, clinical laboratory tests, pregnancy test (for women of child-bearing abilities), assessment of peripheral venous access, and a donor history questionnaire (DHQ). If subjects meet eligibility criteria, they will be asked to undergo two apheresis collections and donate their mononuclear cells (MNCs) for research purposes.

Subjects will be scheduled for the first apheresis collection on study Day 1. Two total blood volume (TBV) will be processed during each apheresis collections, which is currently the collection centers standard practice. All subjects will receive N-803 at a fixed dose of 1 mg by subcutaneous (SC) injection 4 to 5 days prior to the second apheresis collection. The N-803 dose may be administered starting on study Day 8 but no later than study Day 24. The study day for N-803 administration will be determined based on the planned date of the second apheresis collection. The second apheresis collection should occur between study Day 12 and study Day 29. Two TBV will be processed during this collection.

Subjects will be followed for collection of adverse events (AEs) from study Day 1 (first apheresis collection) through the end of study (EOS) visit. Subjects will be instructed to contact the study team in the event they experience AEs post N-803 administration (e.g., injection site reaction). In addition, AEs will be elicited from subjects during follow-up phone calls.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

ImmunityBio, Inc. is the lead sponsor of 83 studies on the registry; 14 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 17 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old.
  • Healthy donors must be free of acute or chronic medical conditions (e.g., hypertension, kidney disease, diabetes, disease, cardiovascular disease).
  • Able to understand and provide a signed that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
  • Adequate organ function, evidenced by the following laboratory results:

(ANC) ≥ 1,000 cells/mm3 count ≥ 100,000 cells/mm3 ≥ 9.0 g/dL Total ≤ 1.5 x (ULN); unless the subject has documented Gilbert's syndrome (ALT)/aspartate aminotransferase (AST) ≤ 3 x ULN Serum creatinine ≤ 2.0 mg/dL or 177 μmol/L

  • Adequate peripheral venous access.
  • Must be able to be in the clinic for up to 6 hours on the day of collection.
  • Must be able to sit or recline with limited movement for approximately 2-3 hours.
  • Must agree to provide blood samples for clinical testing and immunological analysis.
  • (ECOG) performance status of 0.

Exclusion criteria

Exclusion Criteria:

  • Received systemic antibiotics within 14 days prior to apheresis collection.
  • (NYHA) functional assessment score of > Class I.
  • Any medical diagnosis that would prevent the donation of WBCs.
  • History of or active (HIV).
  • Active or .
  • Have been advised by a medical provider not to donate blood.
  • Women who are pregnant or breastfeeding. A negative serum pregnancy test in women of is required at screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Healthy Subjects

    Subjects will be scheduled for first apheresis collection on study Day 1. All subjects will receive N-803 at a fixed dose of 1 mg by subcutaneous (SC) injection 4 to 5 days prior to the second apheresis collection. The study day for N-803 administration will be determined based on the planned date of the second apheresis collection.

    Drug: N-803

Interventions

  • DrugN-803

    fixed dose of 1 mg by subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Incidence of serious adverse events (SAEs) and overall adverse events (AEs) coded in MedDRA

    Incidence of SAEs and overall AEs coded in MedDRA

    Time frame: Study Day 1 through End of Study, assessed up to 45 days

Secondary outcomes

  1. Incidence of serious adverse events (SAEs) and overall adverse events (AEs) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0)

    Incidence of SAEs and overall AEs graded using the NCI CTCAE v5.0

    Time frame: Study Day 1 through End of Study, assessed up to 45 days

  2. Evaluate and compare peripheral blood pre-apheresis and apheresis products collected without N-803 administration (unstimulated) and with N-803 administration (stimulated): - Percentage of NK cells

    \- Percentage of NK cells as measured by flow cytometry.

    Time frame: Study Day 1 through Study Day 24, assessed up to 24 days

  3. Evaluate and compare peripheral blood pre-apheresis and apheresis products collected without N-803 administration (unstimulated) and with N-803 administration (stimulated): - Immune profile

    \- Function and cell receptor profile of NK cells as measured by intracellular staining for cytokines, surface marker staining and assessments of cytotoxicity.

    Time frame: Study Day 1 through Study Day 24, assessed up to 24 days

  4. Evaluate and compare peripheral blood pre-apheresis and apheresis products collected without N-803 administration (unstimulated) and with N-803 administration (stimulated): - Serum cytokines

    \- Serum Cytokines

    Time frame: Study Day 1 through Study Day 24, assessed up to 24 days

Other outcomes

  1. Evaluate + compare the ex vivo expansion + enrichment of NK cells collected by apheresis without N-803 (unstimulated) + with N-803 administration (stimulated) via frequency, number, and phenotype of immune cells measured by flow + mass cytometry.

    \- Frequency, number, and phenotype of immune cells as measured by flow and mass cytometry.

    Time frame: Study Day 1 through Study Day 24, assessed up to 24 days

  2. Exploratory Objective: Evaluate and compare the ex vivo expansion and enrichment of NK cells collected by apheresis without N-803 (unstimulated) and with N-803 administration (stimulated) via Number of days to manufacture CENK and M-CENK.

    \- Number of days to manufacture CENK and M-CENK.

    Time frame: Study Day 1 through Study Day 24, assessed up to 24 days

  3. Exploratory Objective: Evaluate and compare the ex vivo expansion and enrichment of NK cells collected by apheresis without N-803 (unstimulated) and with N-803 administration (stimulated via Quality of CENK and M-CENK cells manufactured.

    \- Quality of CENK and M-CENK cells manufactured measured by the percentage of CD56 adequate for infusion.

    Time frame: Study Day 1 through Study Day 24, assessed up to 24 days

07

Study locations

1 site
  • Chan Soon-Shiong Institute for Medicine
    El Segundo, California 90245, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Sep 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Sep 18, 2023
StartActual
Oct 4, 2023
Primary completionActual
Sep 3, 2024
CompletionActual
Sep 3, 2024
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06040918
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Oct 4, 2023
Primary completion
Sep 3, 2024
Completion
Sep 3, 2024
Last update
Oct 14, 2025

Study contacts

Leonard Sender, MD
study director · ImmunityBio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion